Form 4: Travere Therapeutics Executive Stock Transaction
Statement of Changes in Beneficial Ownership
SVP and Chief Accounting Officer Sandra Calvin exercised stock options and sold shares under a Rule 10b5-1 plan.
Summary
- Sandra Calvin, SVP and Chief Accounting Officer of Travere Therapeutics, exercised options for a total of 15,250 shares of common stock.
- The exercise prices for these options were $22.40, $8.93, and $20.46 per share.
- Following the exercise, 21,977 shares were sold at a market price of $41.07 per share.
- The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on June 10, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it reflects standard executive compensation and liquidity management rather than a change in company outlook.
Positives
- The executive maintains a remaining beneficial ownership of 42,353 shares of common stock.
- The sale was conducted under a pre-arranged Rule 10b5-1 plan, indicating a systematic approach to liquidity rather than reactive trading.
Negatives
- The transaction represents a net reduction in the executive's direct shareholding in the company.
Risks
- Future share price volatility may impact the value of remaining unexercised options.
Future Outlook
No forward-looking guidance regarding company performance was provided in this filing.
Industry Context
StockSavvy.ai notes that routine insider selling under 10b5-1 plans is standard practice for corporate executives in the biotechnology sector to manage personal financial planning and tax obligations.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is a standard governance practice among biotech executives to avoid potential conflicts of interest or accusations of insider trading.
Stakeholder Impact
- Minimal impact on shareholders as the transaction was pre-planned and disclosed in accordance with SEC regulations.
Next Steps
- No future corporate actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 06/10/2025 | Date the Rule 10b5-1 trading plan was adopted. |
| 04/14/2026 | Date of the earliest transaction involving option exercise and share sale. |
| 04/16/2026 | Date the Form 4 was filed with the SEC. |
Keywords
Travere Therapeutics, TVTX, Insider Trading, Form 4, Stock Options, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.